Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK2 | O43353 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 15/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2077909 | 0.85 | ALDH1A1 (0.51) | HSD11B1ALDH1A1GAA | |
| SCHEMBL13838792 | 0.82 | HSD11B1 (0.55) | HSD11B1TSHRALDH1A1GAA | |
| SCHEMBL18307633 | 0.78 | HSD11B1 (0.55) | HSD11B1ALDH1A1GAA | |
| SCHEMBL13819946 | 0.78 | ALDH1A1 (0.49) | HSD11B1ALDH1A1GAA | |
| SCHEMBL19669151 | 0.78 | TP53 (0.52) | HSD11B1KMT2AALDH1A1 | |
| SCHEMBL28824097 | 0.76 | BCAT2 (0.53) | RIPK2ALDH1A1 | |
| SCHEMBL8156087 | 0.74 | TP53 (0.58) | KMT2AALDH1A1GAA | |
| SCHEMBL3168308 | 0.73 | POLB (0.53) | RIPK2KMT2ATSHRALDH1A1 | |
| SCHEMBL29851972 | 0.73 | TSHR (0.44) | HSD11B1KMT2ATSHRALDH1A1GAA | |
| SCHEMBL28824098 | 0.73 | BCAT2 (0.45) | RIPK2TSHRALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9789089-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9789089-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-9789089-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| EP-2943487-B1 | 5-MEMBERED HETEROARYLS AND THEIR USE AS ANTIVIRAL AGENTS | GILEAD SCIENCES INC (US) | 2016-11-16 | — | — | EP | disclosed |
| EP-2943487-B1 | 5-MEMBERED HETEROARYLS AND THEIR USE AS ANTIVIRAL AGENTS | GILEAD SCIENCES INC (US) | 2016-11-16 | — | — | EP | disclosed |
| US-20160067224-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-10 | — | — | US | disclosed |
| US-20160067224-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-10 | — | — | US | disclosed |
| US-20160067224-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-03-10 | — | — | US | disclosed |
| US-9220710-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9220710-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9220710-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| EP-2943487-A1 | 5-MEMBERED HETEROARYLS AND THEIR USE AS ANTIVIRAL AGENTS | Gilead Sciences, Inc. (US) | 2015-11-18 | — | — | EP | disclosed |
| US-20140221421-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221421-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221421-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| WO-2014110298-A1 | 5-MEMBERED HETEROARYLS AND THEIR USE AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2014-07-17 | — | — | WO | disclosed |
| WO-2014110298-A1 | 5-MEMBERED HETEROARYLS AND THEIR USE AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2014-07-17 | — | — | WO | disclosed |
| US-6414013-B1 | KINASE INHIBITORS; ANTICANCER AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2002-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160067224-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | RIPK2 3173/4885HSD11B1 915/4885KMT2A 4702/4885 |
| US-20140221421-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, SARS1, G6PD | RIPK2 3173/4885HSD11B1 915/4885KMT2A 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.